Development of malaria transmission-blocking vaccines: from concept to product

Adv Parasitol. 2015 Jun:89:109-52. doi: 10.1016/bs.apar.2015.04.001. Epub 2015 May 8.

Abstract

Despite decades of effort battling against malaria, the disease is still a major cause of morbidity and mortality. Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. In the 1950s, Huff et al. first demonstrated the induction of transmission-blocking immunity in chickens by repeated immunizations with Plasmodium gallinaceum-infected red blood cells. Since then, significant progress has been made in identification of parasite antigens responsible for transmission-blocking activity. Recombinant technologies accelerated evaluation of these antigens as vaccine candidates, and it is possible to induce effective transmission-blocking immunity in humans both by natural infection and now by immunization with recombinant vaccines. This chapter reviews the efforts to produce TBVs, summarizes the current status and advances and discusses the remaining challenges and approaches.

Keywords: Malaria; Transmission-blocking; Vaccine.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Culicidae / genetics
  • Culicidae / metabolism
  • Humans
  • Insect Proteins / immunology
  • Life Cycle Stages
  • Malaria / prevention & control*
  • Malaria / transmission
  • Malaria Vaccines* / economics
  • Malaria Vaccines* / immunology
  • Malaria Vaccines* / standards
  • Plasmodium / immunology
  • Plasmodium / physiology
  • Protozoan Proteins / genetics
  • Protozoan Proteins / immunology

Substances

  • Insect Proteins
  • Malaria Vaccines
  • Protozoan Proteins